

=====

Sequence Listing could not be accepted due to errors.

See attached Validation Report.

If you need help call the Patent Electronic Business Center at (866) 217-9197 (toll free).

Reviewer: Keisha Douglas

Timestamp: [year=2008; month=10; day=28; hr=16; min=22; sec=44; ms=210;
]

=====

Reviewer Comments:

<220>

<221> MOD_RES

<222> (5)

<223> CH₂OC(CH₃)₃; See specification as filed for structure

<400> 1

His Trp Ser Tyr Xaa Leu Arg Pro

1

5

The above <223> response for "Xaa" location is invalid. FYI, "Xaa" can only represent a single amino acid. Please correct the remaining sequences showing similar errors.

Application No: 10518914 Version No: 1.0

Input Set:

Output Set:

Started: 2008-09-25 12:59:19.581
Finished: 2008-09-25 12:59:20.856
Elapsed: 0 hr(s) 0 min(s) 1 sec(s) 275 ms
Total Warnings: 8
Total Errors: 5
No. of SeqIDs Defined: 8
Actual SeqID Count: 8

Error code	Error Description
W 213	Artificial or Unknown found in <213> in SEQ ID (1)
E 257	Invalid sequence data feature in <221> in SEQ ID (1)
W 213	Artificial or Unknown found in <213> in SEQ ID (2)
W 213	Artificial or Unknown found in <213> in SEQ ID (3)
E 257	Invalid sequence data feature in <221> in SEQ ID (3)
W 213	Artificial or Unknown found in <213> in SEQ ID (4)
E 257	Invalid sequence data feature in <221> in SEQ ID (4)
W 213	Artificial or Unknown found in <213> in SEQ ID (5)
W 213	Artificial or Unknown found in <213> in SEQ ID (6)
E 257	Invalid sequence data feature in <221> in SEQ ID (6)
W 213	Artificial or Unknown found in <213> in SEQ ID (7)
W 213	Artificial or Unknown found in <213> in SEQ ID (8)
E 257	Invalid sequence data feature in <221> in SEQ ID (8)

SEQUENCE LISTING

<110> YAMAMOTO, KAZUMICHI
SAITO, KAZUHIRO
HOSHINO, TETSUO

<120> PROCESS FOR PRODUCING SUSTAINED-RELEASE COMPOSITION

<130> 074129-0516

<140> 10518914

<141> 2008-09-25

<150> PCT/JP03/07950

<151> 2003-06-24

<150> JP 2002-185352

<151> 2002-06-25

<160> 8

<170> PatentIn Ver. 3.3

<210> 1

<211> 8

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
peptide

<220>

<221> MOD_RES

<222> (5)

<223> CH2OC(CH3)3; See specification as filed for structure

<400> 1

His Trp Ser Tyr Xaa Leu Arg Pro

1 5

<210> 2

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
peptide

<400> 2

His Trp Ser Tyr Trp Leu Arg Pro Gly

1 5

<210> 3
<211> 9
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
peptide

<220>
<221> MOD_RES
<222> (5)
<223> CH2(C10H7); See specification as filed for structure

<400> 3
His Trp Ser Tyr Xaa Leu Arg Pro Gly
1 5

<210> 4
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
peptide

<220>
<221> MOD_RES
<222> (5)
<223> CH2(C3N2H2)CH2(C6H5); See specification as filed for structure

<400> 4
His Trp Ser Tyr Xaa Leu Arg Pro
1 5

<210> 5
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
peptide

<400> 5
His Trp Ser Tyr Trp Leu Arg Pro
1 5

<210> 6
<211> 8
<212> PRT
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
peptide

<220>

<221> MOD_RES

<222> (5)

<223> CH₂(C₈NH₅)CH₃; See specification as filed for structure

<400> 6

His Trp Ser Tyr Xaa Leu Arg Pro

1 5

<210> 7

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
peptide

<400> 7

His Trp Ser Tyr Gly Leu Arg Pro Gly

1 5

<210> 8

<211> 8

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
peptide

<220>

<221> MOD_RES

<222> (5)

<223> CH₂OC(CH₃)₃; See specification as filed for structure

<400> 8

His Trp Ser Tyr Xaa Leu Arg Pro

1 5